Data from Pharmawand - Curated by Toby Galbraith - Date added 20 April 2017

The UK's National Institute for Health and Care Excellence has published its final appraisal which backs the use of Cosentyx (secukinumab), from Novartis, in adults with active and progressive psoriatic arthritis. NICE also recommends use of Cosentyx when a patient has peripheral arthritis with three or more tender joints and three or more swollen joints, and has not responded to adequate trials of at least two standard disease-modifying antirheumatic drugs, administered either individually or in combination. It can also be funded for use in those who have had a TNF-alpha inhibitor but have not responded to treatment within the first 12 weeks or have stopped responding after 12 weeks, or when TNF-alpha inhibitors are contraindicated but would otherwise be considered.

Comments

You will need to login, to leave a comment.

epgonline.org is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

IL-17A in Psoriasis

Experts discuss new targeted therapies for psoriasis at the European Association of Dermatology and Venereology (EADV) Congress.

Visit IL-17A in Psoriasis

Psoriasis

See information on psoriasis pathophysiology, signs and symptoms, comorbidities, treatment options, and more.

Visit Psoriasis

Related Content